Nasopharyngeal carcinoma (NPC) is highly prevalent in southeast of Asia, and it is predominantly treated by radiotherapy (RT). Intensity-modulated RT (IMRT) exhibits better dosimetric advantages over two-dimensional RT (2D-RT) or three-dimensional conformal RT (3D-CRT). It has significantly improved the local control rate of NPC and reduced acute and chronic toxicities. Helical TomoTherapy® was an emerging technology that integrates IMRT, image-guided intensity modulated radiotherapy (IGRT) and dose-guided intensity modulated radiotherapy (DGRT). TomoTherapy makes a perfect combination of linear accelerator and helical CT, breaking through many limitations of traditional accelerator. While rotating the irradiation target area, the treatment couch advances axially through the center of the stand, which is used to treat tumors efficiently and accurately. This webinar will focus on the treatment of NPC by TomoTherapy. Firstly, describing the therapeutic mechanism of TomoTherapy, the advantages and limitations of TomoTherapy in the treatment of tumors. This webinar will explain how to implement TomoTherapy in a patient with NPC. Finally, the experience of treating NPC by TomoTherapy in the Sun Yat-sen University Cancer Center, Guangzhou, China will be shared.
1. Describe the therapeutic mechanism of TomoTherapy®.
2. Explain the characteristics of TomoTherapy® in the treatment of cancer.
3. Explain the implementation of TomoTherapy® in treating patients with nasopharyngeal carcinoma.
Fei Han, M.D., Ph.D., Sun Yat-sen University Cancer Center, Guangzhou, China
Dr. Han has rich experience in the field of clinical radiation oncology, especially in head & neck cancer and nasopharyngeal carcinoma. He has also made great contribution to the clinical management of locally recurrent nasopharyngeal carcinoma. Dr. Han has published more than 190 research papers and selected. Dr. Han obtained his Ph.D. degree of Oncology on June 25th, 2012. Dr. Han is President, Professional Board for Radiotherapy, Guangdong Provincial Anti-Cancer Association, Member, Professional Board for Nasopharyngeal Carcinoma, Chinese Anti-Cancer Association (CACA), Member, Professional Board for Radiation Oncology, CACA, Member of Standing Committee, Expert Board for Head and Neck Cancer, Chinese Society of Clinical Oncology (CSCO) and Vice-President, Biology Group of Radiation Oncology Branch, Chinese Medical Association (CMA).
Moderated by: Italo Dell’Oca M.D., San Raffaele Scientific Institute, Milan, Italy
Dr. Dell’Oca is Senior Assistant, Division of Radiotherapy, San Raffaele Scientific Institute, Milan, Italy. He is a Head & Neck and Lung cancer specialist. He has collaboration in several research projects with the Italian Association of Cancer Research (AIRC) and San Raffaele Scientific Institute. His research interests are Head and Neck malignancies, Lung cancer, combined modality approach, high precision radiotherapy (stereotactic radiotherapy, IMRT, IGRT etc.), new fractionation protocols, imaging in radiotherapy and new prognostic and predictive parameters. He has a broad teaching experience within regular pre- and postgraduate university activities.